作者

Dr. Manja Epping

合伙人

Read More

Evelyne Friedel

合伙人

Read More

Judith Krens

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More
作者

Dr. Manja Epping

合伙人

Read More

Evelyne Friedel

合伙人

Read More

Judith Krens

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More

2019年5月30日 |

Recent legislative developments affecting biologics and biosimilars

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. Recently, a flurry of proposed legislation has threatened to drastically alter the US regulation of and policies on wide ranging topics such as drug pricing, mandatory licensing, patent thickets, and the availability of post-grant proceedings.

In session 2 of this series we focus on key factors decision makers need to be aware of when considering currently pending legislation, including:

  • Key provisions of proposed legislation
  • European perspectives and approaches to similar issues

View session 1


Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

酒店与休闲

Biologics and biosimilars litigation update

2020年11月25日
Quick read

作者

点击此处了解更多
centrifuge-machine
酒店与休闲

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

2020年7月27日
QUICK READ

作者

点击此处了解更多
woman-with-scientific-model
酒店与休闲

Everything biologic and biosimilar in-house counsel need to know about COVID-19

2020年4月29日

作者

点击此处了解更多

相关活动